Following the use of IL-2 as a T-cell growth factor in the treatment of patients with metastatic melanoma and renal cell cancer (RCC), manipulation of the host immune system has been suggested to elicit an endogenous reaction capable of mediating cancer regression. The gene discussed is IL2; the disease is metastatic melanoma.